Translational medicine, biomarkers and personalised medicine
The drug discovery and development process is undergoing radical change.
- Regulators, research councils, charities and pharma companies are committing increasing priority and resource to a new type of (‘translational’) study between traditional discovery and development.
- Translational medicine seeks to expose drug discovery pipelines to an intense dose of clinical scrutiny based on clinical insight, tissue samples, pharmacogenomics, patient data bio-informatics.
- Powerful new biomarkers are being identified which will enable far greater powers of disease prediction and treatment efficacy and toxicology.
This development has potentially major implications:
- Demand for new technologies (microprocessing, imaging)
- Major new biomarker licensing and product development opportunities
- New markets for niche medicines
- Ultimately the rise of personalised predictive medicine, and
- The growth of major consumer healthcare ‘wellness’ market
In 2005 we carried out a major research project into translational medicine collaborations around the world, and subsequently advised on the $50m biomarker collaboration recently announced by Wyeth (see case study).
Contact us to find out more about how we could help you…